Antibiotic Resistance: India’s Growing Health Risk

UPSC Mapping

Prelims

• Microbiology, One Health and AWaRe Classification

Mains

• GS Paper III: Science, Health and Biosecurity

Quick Facts

Indian Framework	NAP-AMR 2.0
Plan Period	2025–2029
Global Surveillance	WHO GLASS
Core Approach	One Health

What is Antibiotic Resistance?

Antibiotic Resistance occurs when bacteria change in ways that reduce or eliminate the effectiveness of medicines designed to kill them or stop their growth. The patient does not become resistant; the bacterial population develops or acquires traits that survive treatment. Resistant organisms can then multiply, spread between people and environments, and make previously manageable infections difficult to cure across hospitals, communities and food systems.

Antibiotics act only against bacterial infections, while the broader term antimicrobial resistance also covers resistance in viruses, fungi and parasites. Misuse and overuse accelerate natural selection by exposing microbes to medicines without reliably eliminating them. Incomplete treatment, unnecessary prescriptions and poor infection control create additional opportunities for resistant strains to survive and circulate.

Why is Antibiotic Resistance in News?

Antibiotic Resistance is in news after a multicentre ICMR study examined infections at 20 tertiary hospitals between April 2022 and April 2025. The analysis covered more than 26,000 patients with confirmed infections caused by important Gram-negative bacteria. About 61.1% of studied infections involved organisms resistant to carbapenems, powerful broad-spectrum antibiotics often reserved for severe cases.

Researchers compared carbapenem-resistant infections with susceptible infections and found greater mortality, longer treatment burdens and higher antibiotic costs in resistant cases. The results differed by organism, infection site and patient condition, so they do not establish one uniform risk for every hospital patient and require interpretation within clinical context. Aspirants can examine the methods and organism-specific findings in the ICMR surveillance network rather than treating resistance as a single undifferentiated outcome.

Key Features

The problem combines microbial evolution with medicine use, health-system capacity, agriculture and environmental pathways. Effective control therefore requires coordinated evidence and action across several administrative sectors.

• Selection drives survival: Antibiotic exposure kills susceptible bacteria but may leave resistant variants alive, allowing them to reproduce and become a larger share of the microbial population.
• Genes can spread horizontally: Bacteria may exchange resistance genes through mobile genetic elements, enabling useful survival traits to move across strains or species without waiting for slow generational mutation.
• Carbapenems protect last-line care: Clinicians use these broad-spectrum medicines for severe infections when safer or narrower options fail, making carbapenem resistance especially dangerous for intensive care and complex surgery.
• Transmission crosses sectors: Resistant organisms and residues can move among humans, animals, food, soil and water, which makes coordinated One Health surveillance essential for prevention and source control.
• Resistance raises system costs: Failed first-line treatment can require expensive diagnostics, prolonged hospitalisation, isolation, stronger medicines and closer monitoring, while families also face lost income and caregiving burdens.

The ICMR study focused on four clinically important Gram-negative bacteria: Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa. These organisms can cause bloodstream, urinary, respiratory and device-associated infections, especially among critically ill or immunocompromised patients. Their outer-membrane structure, acquired enzymes and other defence mechanisms can limit drug entry, destroy medicines or remove them from bacterial cells.

WHO’s AWaRe framework groups antibiotics as Access, Watch and Reserve to support appropriate selection and stewardship. Access medicines usually serve as preferred options for common infections, while Watch medicines have higher resistance potential and need closer monitoring. Reserve medicines protect treatment for multidrug-resistant infections, and the global target seeks at least 70% Access-group use by 2030.

Challenges

India faces a dual challenge of curbing irrational antibiotic use while ensuring timely access for patients who genuinely need treatment. Policy must reduce avoidable exposure without delaying essential care for bacterial disease.

• Empirical treatment remains common: Limited rapid diagnostics can push clinicians towards broad-spectrum medicines before laboratory results arrive, increasing selection pressure when infection control and review systems remain weak.
• Non-prescription access persists: Self-medication, informal sales and patient demand can encourage unnecessary use for viral illnesses, incorrect doses or premature discontinuation when symptoms begin to improve.
• Hospital capacity varies: Overcrowding, inadequate isolation, inconsistent hand hygiene, device-associated infections and limited microbiology services allow resistant organisms to emerge and spread within healthcare facilities.
• Animal and environmental pathways matter: Antibiotic use in livestock and aquaculture, pharmaceutical discharge, sewage and untreated healthcare waste can expose microbes outside hospitals and circulate resistance genes across ecosystems.
• Innovation incentives are weak: New antibiotics must be used sparingly to preserve effectiveness, limiting commercial returns even though society urgently needs new drugs, diagnostics, vaccines and alternative therapies.

Surveillance data also require careful interpretation because tertiary hospitals treat sicker patients and may record higher resistance than community settings. Laboratories use different capacities, patient mixes and sampling practices, making comparisons difficult without standard methods and clinical context. CBL’s science and technology coverage helps relate laboratory evidence to governance, agriculture and public health.

Unequal access creates another policy tension because some communities overuse antibiotics while others cannot obtain effective medicines, cultures or qualified care. Restriction without stronger primary healthcare can delay treatment and push patients towards unregulated markets. Stewardship must therefore combine prescription accountability, affordable diagnostics and reliable medicine supply rather than treating reduced consumption as the only objective.

Way Forward

Hospitals should connect laboratory resistance data with patient outcomes, antibiotic use and infection-control audits. Rapid diagnostics and antimicrobial susceptibility testing can help clinicians shift from broad empirical treatment to the narrowest effective medicine. Health systems must strengthen stewardship teams, hand hygiene and device safety while auditing prescriptions without obstructing emergency care.

India’s NAP-AMR 2.0 should coordinate health, veterinary, agriculture, food, pharmaceutical and environmental authorities through measurable One Health targets. Regulators need enforceable standards for antibiotic sales, manufacturing effluent and farm use, supported by awareness and accessible care. The NCDC antimicrobial resistance programme outlines the national response; sustained implementation can contain Antibiotic Resistance while protecting equitable access to life-saving treatment.

Prelims Practice Corner

1. Q1. In antibiotic resistance, which entity primarily becomes resistant?

   • (a) Human body
   • (b) Bacterial population
   • (c) Hospital building
   • (d) Vaccine vial

   Answer: (b) Bacteria develop or acquire traits that reduce a medicine’s effectiveness.

2. Q2. Which of the following correctly describes carbapenems?

   • (a) Antiviral vaccines
   • (b) Broad-spectrum antibiotics used for severe infections
   • (c) Antifungal disinfectants only
   • (d) Nutritional supplements

   Answer: (b) Carbapenems are powerful broad-spectrum antibiotics often used when other treatments may fail.

3. Q3. Under WHO’s AWaRe classification, Reserve antibiotics are primarily intended for what purpose?

   • (a) Routine viral fever
   • (b) Multidrug-resistant infections
   • (c) Nutritional deficiency
   • (d) Universal preventive use

   Answer: (b) Reserve medicines protect options for infections with limited effective alternatives.

4. Q4. Consider the following pathways: 1. Human healthcare 2. Livestock production 3. Pharmaceutical effluent 4. Wastewater. How many can contribute to antimicrobial resistance?

   • (a) Only one
   • (b) Only two
   • (c) Only three
   • (d) All four

   Answer: (d) One Health recognises interconnected human, animal and environmental pathways.

5. Q5. Which intervention most directly supports targeted antibiotic treatment?

   • (a) Antimicrobial susceptibility testing
   • (b) Automatic broad-spectrum prescribing
   • (c) Stopping all laboratory testing
   • (d) Treating every fever with antibiotics

   Answer: (a) Susceptibility testing identifies medicines likely to work against the isolated organism.

Mains Practice Questions

1. Q1. Antimicrobial resistance is simultaneously a medical, developmental and environmental challenge. Discuss through a One Health framework. (15 marks)

   Answer Structure:

   • Intro: Define resistance and explain its cross-sectoral nature.
   • Body: Cover human use, livestock, environment, surveillance, infection control, diagnostics, access and innovation.
   • Conclusion: Recommend accountable coordination under NAP-AMR 2.0.

2. Q2. Examine why antimicrobial stewardship must balance conservation of antibiotics with equitable access to effective treatment. (10 marks)

   Answer Structure:

   • Intro: Present overuse and inadequate access as a dual public-health burden.
   • Body: Discuss prescription audits, diagnostics, AWaRe, primary care, affordability and emergency treatment.
   • Conclusion: Support rational use without denying clinically necessary medicines.

FAQs on Antibiotic Resistance

Can antibiotics treat viral infections?

No. Antibiotics target bacteria and do not cure viral illnesses such as influenza. Unnecessary use can expose harmless or disease-causing bacteria to selection pressure.

Why is carbapenem resistance especially concerning?

Carbapenems often treat severe infections when narrower antibiotics may not work. Resistance can leave clinicians with fewer, costlier or more toxic treatment options.

What does the One Health approach mean for resistance control?

It coordinates action across human health, animal health, agriculture, food and the environment. This approach recognises that resistant organisms and antimicrobial residues move across these connected systems.